InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
Subscribe Login/Register
S&P 500
5,127.79
(
1.26%
)
US TECH 100
17,446.00
(
2.17%
)
Dow Jones
38,675.68
(
1.18%
)
Brent Oil
82.77
(
0.00%
)
Bitcoin
63,940.46
(
1.67%
)
Post# of 251711
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Replies (4) Keep Next 10 Report Keyboard Shortcuts
Replies (4) Next 10 Prev Next

dewophile

Send PM Follow Ignore
Followers 44
Posts 4529
Boards Moderated 0
Alias Born 07/19/2006

dewophile

Re: DewDiligence post# 235403

Friday, 04/23/2021 10:34:58 AM

Friday, April 23, 2021 10:34:58 AM

Post# of 251711
BMY

https://investors.bms.com/iframes/press-releases/press-release-details/2021/Bristol-Myers-Squibb-Presents-Positive-Data-from-Two-Pivotal-Phase-3-Psoriasis-Studies-Demonstrating-Superiority-of-Deucravacitinib-Compared-to-Placebo-and-Otezla-apremilast/default.aspx

The efficacy beat vs Otezla seems substantial. Nothing about safety in this PR raises alarms to me. This could be a big drug for BMY. It could be a really big drug if it also works well in other autoimmune conditions, although the space is obviously competitive

EDIT: I see you beat me to it and posted the slides..
Public Reply Private Reply New Post
Keep Last Read
Replies (4) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (4) Next 10 Prev Next

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up